Premenopausal Osteoporosis.
Premenopausal Osteoporosis.
复制标题
DOI：
10.1016/j.ecl.2016.09.007
复制
发表时间：
2017-03
影响因子：
4.5
通讯作者：
Cohen A
中科院分区：
文献类型：
--
作者：
Cohen A
大多数低创伤骨折或低BMD的绝经前妇女有骨质疏松症或骨丢失的次要原因。存在不明原因骨折或低BMD的女性应进行全面的临床和实验室评估，以寻找骨折和/或骨质流失的已知原因。在可能的情况下，治疗的根本原因应是管理的重点。绝经前妇女骨丢失的持续原因和那些谁有，或继续有，低创伤骨折可能需要药物干预。临床试验提供了双膦酸盐和特立哌酮对几种类型的绝经前骨质疏松症的骨密度有益的证据，但研究规模较小，没有提供有关骨折风险降低的证据。
Most premenopausal women with low trauma fracture(s) or low BMD have a secondary cause of osteoporosis or bone loss. Women who present with unexplained fractures or low BMD should have a thorough clinical and laboratory evaluation to search for known causes of fractures and/or bone loss. Where possible, treatment of the underlying cause should be the focus of management. Premenopausal women with an ongoing cause of bone loss and those who have had, or continue to have, low trauma fractures may require pharmacological intervention. Clinical trials provide evidence of benefits of bisphosphonates and teriparatide for bone mineral density in several types of premenopausal osteoporosis, but studies are small and do not provide evidence regarding fracture risk reduction.